PhaseRx, Inc. (NASDAQ:PZRX) issued its quarterly earnings data on Thursday. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.09, Bloomberg Earnings reports.

Shares of PhaseRx (PZRX) traded down 0.4493% during trading on Friday, reaching $0.6869. The company had a trading volume of 68,040 shares. The stock’s market capitalization is $8.03 million. The stock’s 50-day moving average price is $0.82 and its 200-day moving average price is $1.24. PhaseRx has a 12 month low of $0.01 and a 12 month high of $3.98.

TRADEMARK VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/11/phaserx-inc-nasdaqpzrx-announces-quarterly-earnings-results-misses-estimates-by-0-09-eps.html.

An institutional investor recently raised its position in PhaseRx stock. Vanguard Group Inc. raised its stake in shares of PhaseRx, Inc. (NASDAQ:PZRX) by 4.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 142,182 shares of the company’s stock after buying an additional 5,500 shares during the period. Vanguard Group Inc. owned 1.22% of PhaseRx worth $135,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 1.95% of the company’s stock.

Separately, ValuEngine cut PhaseRx from a “sell” rating to a “strong sell” rating in a report on Friday, May 19th.

PhaseRx Company Profile

PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.

Receive News & Stock Ratings for PhaseRx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseRx Inc. and related stocks with our FREE daily email newsletter.